5-Fluorouracil/folinic acid plus oxaliplatin (FUFOX, arm A) versus capecitabine plus oxaliplatin (CAPOX, arm B) in the treatment of advanced colorectal carcinoma (ACRC)
HT Arkenau, B Petershagen, U Graeven, W Schmiegel, A Grothey, HJ Schmoll, P Reichardt, G Adler, A Hinke, R Porschen · Zeitschrift für Gastroenterologie · 2015 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background: In a previous phase III study the FUFOX regimen has shown higher antitumor activity in comparison to the standard 5-FU/FA (Mayo clinic) regimen in patients with advanced colorectal cancer (Proc ASCO 2001, A 496). Also, the combination of CAP and OX showed good efficacy and toxicity results in phase II studies (Proc ASCO 2001, A 546; ECCO 2001, A 1005). Therefore, we compared the toxicity and efficacy of both regimens in this phase III study. Patients and methods: All patients had measurable ACRC, ECOG performance status 0–2, normal bone marrow, renal and hepatic function. Today 133 patients were rand…
